244 related articles for article (PubMed ID: 20184211)
1. Clobetasol propionate shampoo 0.05% is efficacious and safe for long-term control of scalp psoriasis.
Poulin Y; Papp K; Bissonnette R; Guenther L; Tan J; Lynde C; Kerrouche N; Villemagne H;
Cutis; 2010 Jan; 85(1):43-50. PubMed ID: 20184211
[TBL] [Abstract][Full Text] [Related]
2. Clobetasol propionate shampoo 0.05% is efficacious and safe for long-term control of moderate scalp psoriasis.
Poulin Y; Papp K; Bissonnette R; Barber K; Kerrouche N; Villemagne H;
J Dermatolog Treat; 2010 May; 21(3):185-92. PubMed ID: 20131980
[TBL] [Abstract][Full Text] [Related]
3. Clobetasol propionate shampoo 0.05%: a new option to treat patients with moderate to severe scalp psoriasis.
Jarratt M; Breneman D; Gottlieb AB; Poulin Y; Liu Y; Foley V
J Drugs Dermatol; 2004; 3(4):367-73. PubMed ID: 15303780
[TBL] [Abstract][Full Text] [Related]
4. Short-term safety assessment of clobetasol propionate 0.05% shampoo: hypothalamic-pituitary-adrenal axis suppression, atrophogenicity, and ocular safety in subjects with scalp psoriasis.
Andres P; Poncet M; Farzaneh S; Soto P
J Drugs Dermatol; 2006 Apr; 5(4):328-32. PubMed ID: 16673799
[TBL] [Abstract][Full Text] [Related]
5. A randomized, investigator-masked clinical evaluation of the efficacy and safety of clobetasol propionate 0.05% shampoo and tar blend 1% shampoo in the treatment of moderate to severe scalp psoriasis.
Griffiths CE; Finlay AY; Fleming CJ; Barker JN; Mizzi F; Arsonnaud S
J Dermatolog Treat; 2006; 17(2):90-5. PubMed ID: 16766333
[TBL] [Abstract][Full Text] [Related]
6. Short-contact clobetasol propionate shampoo 0.05% improves quality of life in patients with scalp psoriasis.
Tan J; Thomas R; Wang B; Gratton D; Vender R; Kerrouche N; Villemagne H;
Cutis; 2009 Mar; 83(3):157-64. PubMed ID: 19363909
[TBL] [Abstract][Full Text] [Related]
7. Clobetasol propionate shampoo 0.05% and calcipotriol solution 0.005%: a randomized comparison of efficacy and safety in subjects with scalp psoriasis.
Reygagne P; Mrowietz U; Decroix J; de Waard-van der Spek FB; Acebes LO; Figueiredo A; Caputo R; Poncet M; Arsonnaud S
J Dermatolog Treat; 2005 Feb; 16(1):31-6. PubMed ID: 15897165
[TBL] [Abstract][Full Text] [Related]
8. Treatment of scalp psoriasis with clobetasol-17 propionate 0.05% shampoo: a study on daily clinical practice.
Bovenschen HJ; Van de Kerkhof PC
J Eur Acad Dermatol Venereol; 2010 Apr; 24(4):439-44. PubMed ID: 19845822
[TBL] [Abstract][Full Text] [Related]
9. Efficacious and safe management of moderate to severe scalp seborrhoeic dermatitis using clobetasol propionate shampoo 0·05% combined with ketoconazole shampoo 2%: a randomized, controlled study.
Ortonne JP; Nikkels AF; Reich K; Ponce Olivera RM; Lee JH; Kerrouche N; Sidou F; Faergemann J
Br J Dermatol; 2011 Jul; 165(1):171-6. PubMed ID: 21707573
[TBL] [Abstract][Full Text] [Related]
10. Clobetasol propionate 0.05% spray for the management of moderate-to-severe plaque psoriasis of the scalp: results from a randomized controlled trial.
Sofen H; Hudson CP; Cook-Bolden FE; Preston N; Colón LE; Colón LE; Caveney SW; Gottschalk RW
J Drugs Dermatol; 2011 Aug; 10(8):885-92. PubMed ID: 21818510
[TBL] [Abstract][Full Text] [Related]
11. Clobetasol propionate shampoo 0.05% in the treatment of seborrheic dermatitis of the scalp: results of a pilot study.
Reygagne P; Poncet M; Sidou F; Soto P
Cutis; 2007 May; 79(5):397-403. PubMed ID: 17569404
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the efficacy and safety of clobetasol propionate spray in the treatment of plaque-type psoriasis.
Jarratt MT; Clark SD; Savin RC; Swinyer LJ; Safley CF; Brodell RT; Yu K
Cutis; 2006 Nov; 78(5):348-54. PubMed ID: 17186795
[TBL] [Abstract][Full Text] [Related]
13. An intra-individual randomized safety and efficacy comparison of clobetasol propionate 0.05% spray and its vehicle in the treatment of plaque psoriasis.
Beutner K; Chakrabarty A; Lemke S; Yu K
J Drugs Dermatol; 2006 Apr; 5(4):357-60. PubMed ID: 16673804
[TBL] [Abstract][Full Text] [Related]
14. Impact of clobetasol propionate 0.05% spray on health-related quality of life in patients with plaque psoriasis.
Menter MA; Caveney SW; Gottschalk RW
J Drugs Dermatol; 2012 Nov; 11(11):1348-54. PubMed ID: 23135087
[TBL] [Abstract][Full Text] [Related]
15. Clobetasol propionate spray 0.05% add-on therapy to a stable regimen of biologic treatment in patients with moderate to very severe plaque psoriasis.
Feldman SR; Koo JY; Johnson LA; Preston NJ
Cutis; 2009 Oct; 84(4 Suppl):25-32. PubMed ID: 19916299
[TBL] [Abstract][Full Text] [Related]
16. A double-blind, vehicle-controlled study of clobetasol propionate 0.05% (Temovate) scalp application in the treatment of moderate to severe scalp psoriasis.
Olsen EA; Cram DL; Ellis CN; Hickman JG; Jacobson C; Jenkins EE; Lasser AE; Lebwohl M; Leibsohn E; Medansky RS
J Am Acad Dermatol; 1991 Mar; 24(3):443-7. PubMed ID: 2061442
[TBL] [Abstract][Full Text] [Related]
17. Clobetasol propionate emulsion formulation foam 0.05%: review of phase II open-label and phase III randomized controlled trials in steroid-responsive dermatoses in adults and adolescents.
Kimball AB; Gold MH; Zib B; Davis MW;
J Am Acad Dermatol; 2008 Sep; 59(3):448-54, 454.e1. PubMed ID: 18539358
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of twice-daily augmented betamethasone dipropionate lotion versus clobetasol propionate solution in patients with moderate-to-severe scalp psoriasis.
Katz HI; Lindholm JS; Weiss JS; Shavin JS; Morman M; Bressinck R; Cornell R; Pariser DM; Pariser RJ; Weng W
Clin Ther; 1995; 17(3):390-401. PubMed ID: 7585843
[TBL] [Abstract][Full Text] [Related]
19. Scalp psoriasis.
Kircik LH; Kumar S
J Drugs Dermatol; 2010 Aug; 9(8 Suppl ODAC Conf Pt 2):s101-5. PubMed ID: 20715392
[TBL] [Abstract][Full Text] [Related]
20. An open-label, multicenter study of the efficacy and safety of a weekday/weekend treatment regimen with calcitriol ointment 3 microg/g and clobetasol propionate spray 0.05% in the management of plaque psoriasis.
Hudson CP; Kempers S; Menter A; Papp K; Smith S; Sofen H; Colón LE; Johnson LA; Gottschalk R
Cutis; 2011 Oct; 88(4):201-7. PubMed ID: 22106730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
